Home › Research › TREM2 and immune genetics
Resolving the fibrotic niche of human liver cirrhosis at single-cell level
Ramachandran P, Dobie R, Wilson-Kanamori JR, Dora EF, Henderson BEP, Luu NT, Portman JR, Matchett KP et al.. Nature, 2019-10-09
Topic: Brain proteins, microglia and lab models
Plain-language summary
Liver cirrhosis is a major cause of death worldwide and is characterized by extensive fibrosis. There are currently no effective antifibrotic therapies available. To obtain a better understanding of the cellular and molecular mechanisms involved in disease pathogenesis and enable the discovery of therapeutic targets, here we profile the transcriptomes of more than 100,000 single human cells, yielding molecular definitions for non-parenchymal cell types that are found in healthy and cirrhotic human liver.
What this study adds
Evidence grade: Low
By profiling more than 100,000 single cells from healthy and cirrhotic human liver, this study reports a scar-associated TREM2+CD9+ macrophage group that expands in liver fibrosis, comes from circulating monocytes and is described as pro-fibrogenic. It also reports ACKR1+ and PLVAP+ blood-vessel cells that gather in the scarred areas.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ramachandran, P., Dobie, R., Wilson-Kanamori, JR., Dora, E. F., Henderson, B. E. P., Luu, N. T., et al. (2019). Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature. https://doi.org/10.1038/s41586-019-1631-3
Vancouver
Ramachandran P, Dobie R, Wilson-Kanamori JR, Dora EF, Henderson BEP, Luu NT, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature. 2019. doi:10.1038/s41586-019-1631-3. PMID: 31597160.
BibTeX
@article{ramachandran2019-31597160,
author = {Ramachandran, P. and Dobie, R. and Wilson-Kanamori, JR. and Dora, E. F. and Henderson, B. E. P. and Luu, N. T. and Portman, JR. and Matchett, K. P. and others},
title = {{Resolving the fibrotic niche of human liver cirrhosis at single-cell level}},
journal = {Nature},
year = {2019},
doi = {10.1038/s41586-019-1631-3},
pmid = {31597160},
url = {https://doi.org/10.1038/s41586-019-1631-3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- There are currently no effective antifibrotic therapies available.
- To obtain a better understanding of the cellular and molecular mechanisms involved in disease pathogenesis and enable the discovery of therapeutic targets, here we profile the transcriptomes of more than 100,000 single human cells, yielding molecular definitions for non-parenchymal cell types that are found in healthy and cirrhotic human liver.
- We identify a scar-associated TREM2 + CD9 + subpopulation of macrophages, which expands in liver fibrosis, differentiates from circulating monocytes and is pro-fibrogenic.
- We also define ACKR1 + and PLVAP + endothelial cells that expand in cirrhosis, are topographically restricted to the fibrotic niche and enhance the transmigration of leucocytes.
Why it matters
By profiling more than 100,000 single cells from healthy and cirrhotic human liver, this study reports a scar-associated TREM2+CD9+ macrophage group that expands in liver fibrosis, comes from circulating monocytes and is described as pro-fibrogenic. It also reports ACKR1+ and PLVAP+ blood-vessel cells that gather in the scarred areas. It is a liver study that tested no treatment and says nothing directly about Alzheimer's disease; its relevance here is that it describes TREM2-carrying immune cells in human tissue.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 64/100
Published in a top-tier journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (Nature) |
| Journal's citation record | 4 / 4 | Nature: journal h-index 1,841 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 1,770 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 196.7 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 6 / 6 | Cited 79.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 26 other studies in this library |
| Still being cited | 4 / 4 | Cited 900 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Neil Cowan Henderson: h-index 65 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Cambridge: institution h-index 1,973 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 19 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31597160) |
| Free to read | 2 / 2 | Free to read |
| Total | 64 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41586-019-1631-3
- PubMed: 31597160
- Original source →
- Free full text: bioRxiv (Cold Spring Harbor Laboratory) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Later studies that cite this one
26 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in TREM2 and immune genetics from nearby years
Also in TREM2 and immune genetics
83 studies in the library are filed under TREM2 and immune genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The TREM2 and immune genetics hub.